Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

HLA-DRB1 does not have a role in clinical response to interferon-beta among Iranian multiple sclerosis patients.

Journal of the neurological sciences - 15 May 2015

Samadzadeh Sara, Tabibian Elnaz, Sabokbar Tayebeh, Shakoori Abbas, Dehgolan Shahram Rahimi, Armaki Saeed Azad, Aslanbeigi Bahram, Abolfazli Roya

Abstract excerpt

BACKGROUND & OBJECTIVES: The role of human leukocyte antigen (HLA) in clinical response to immunotherapy is not completely known. In this study we evaluated the relationship between HLA-DRB1 genotype, which has been proved to be more common in Iranian MS patients, and clinical response to interfe...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Follow-Up Studies
Share to HLA-DRB1 Chains
Share to Immunologic Factors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immunotherapy

Share to Interferon-beta

Share to Magnetic Resonance Imaging

Share to Multiple Sclerosis, Relapsing-Remitting

Source

Identifiers

PMID: 25824849
DOI: 10.1016/j.jns.2015.03.004

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-25824849-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

HLA-DRB1 does not have a role in clinical response to interferon-beta among Iranian multiple sclerosis patients.PMID 25824849Read ↗

HLA Genes as Modifiers of Response to IFN-β-1a Therapy in Relapsing-Remitting Multiple SclerosisSemantic proximity Read ↗

HLA class I and II alleles and response to treatment with interferon-beta in relapsing-remitting multiple sclerosis.Semantic proximity Read ↗

TRAILR1 (rs20576) and GRIA3 (rs12557782) are not associated with interferon-β response in multiple sclerosis patients.Semantic proximity Read ↗

HLA class II and response to interferon-beta in multiple sclerosis.Semantic proximity Read ↗

Genetic Variant HLA-DRB1*0403 and Therapeutic Response to Disease-Modifying Therapies in Multiple Sclerosis: A Case-Control Study.Semantic proximity Read ↗

Genetic Variant HLA DRB1*0403 and Therapeutic Response to Diseases Modifying Therapies in Multiple Sclerosis: A Case‐Control StudySemantic proximity Read ↗

HLA class II (DRB1, DQA1 and DQB1) associated genetic susceptibility in Iranian multiple sclerosis (MS) patients.Semantic proximity Read ↗

Relationship between HLA-DRB1* 11/15 genotype and susceptibility to multiple sclerosis in Iran.Semantic proximity Read ↗

Association study of promoter polymorphisms of interferon alpha and beta receptor subunit 1 (IFNAR1) gene and therapeutic response to interferon-beta in patients with multiple sclerosis.Semantic proximity Read ↗

Myxovirus resistance protein A (MxA) polymorphism is associated with IFNβ response in Iranian multiple sclerosis patients.Semantic proximity Read ↗

Relationship between HLA-DRB1 polymorphism and susceptibility or resistance to multiple sclerosis in Caucasians: a meta-analysis of non-family-based studies.Semantic proximity Read ↗

Altered Immune Phenotypes and HLA-DQB1 Gene Variation in Multiple Sclerosis Patients Failing Interferon β Treatment.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.